Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $25.89, for a total value of $6,472,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
YMAB traded up $0.18 during midday trading on Friday, hitting $22.82. The company’s stock had a trading volume of 48,330 shares, compared to its average volume of 73,132. The stock has a market capitalization of $780.31 million and a price-to-earnings ratio of -15.21. Y-mAbs Therapeutics, Inc has a 52-week low of $15.17 and a 52-week high of $31.00.
Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.11). Equities research analysts predict that Y-mAbs Therapeutics, Inc will post -1.67 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in YMAB. Citigroup Inc. acquired a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $37,000. Strs Ohio acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $38,000. BNP Paribas Arbitrage SA acquired a new position in Y-mAbs Therapeutics during the 1st quarter worth approximately $38,000. American International Group Inc. acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $93,000. Finally, Bank of America Corp DE lifted its position in Y-mAbs Therapeutics by 3,056.5% during the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after acquiring an additional 5,838 shares in the last quarter. 25.41% of the stock is currently owned by institutional investors and hedge funds.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.